US Insurer Sues J&J For ‘Unlawfully’ Holding Up Stelara Biosimilars
Originator’s Alleged Unlawful Conduct Set To Cost Purchasers Upwards Of $1bn
Executive Summary
In the wake of several settlement deals with biosimilar sponsors, Johnson & Johnson has been sued for allegedly “implementing a scheme to unlawfully prolong patent protection for Stelara well beyond September 2023.”